Literature DB >> 3015271

Pathophysiology of "cholinoceptor supersensitivity" in affective disorders.

S C Dilsaver.   

Abstract

Phenomenological and physiological variables demonstrate supersensitive changes to cholinergic challenge in affective disorder subjects. Theorists generally assume the primary defect is the postsynaptic muscarinic receptor. However, in addition to defectiveness or up-regulation of this receptor, the appearance of postsynaptic "cholinoceptor supersensitivity" can result from abnormal presynaptic mechanisms, membrane "pathology," derangement of intrasystolic mechanisms that amplify effects of receptor-agonist coupling, or aberrant cholinergic-monoaminergic interaction. This article discusses abnormalities of the postsynaptic receptor, regulation of postsynaptic receptor density, the presynaptic muscarinic receptor, and other mechanisms regulating the release of acetylcholine, membrane dynamics, and "cascade" mechanisms-specifically the phosphatidylinositol (PI) cycle, Ca2+ mobilization, and cyclic guanosine monophosphate (GMP) generation-as causes of cholinergic system "supersensitivity." It is suggested that an approach to the topic emphasizing site of abnormality will encourage greater clarity of thought in the study of the cholinergic component of the pathophysiology of affective illness.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015271     DOI: 10.1016/0006-3223(86)90246-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

1.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

Review 2.  Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.

Authors:  Maura L Furey; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

3.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

4.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

5.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

6.  Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  Wayne C Drevets; Maura L Furey
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 7.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

Review 8.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

9.  Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography.

Authors:  Jonas O Hannestad; Kelly P Cosgrove; Nicole F DellaGioia; Evgenia Perkins; Frederic Bois; Zubin Bhagwagar; John P Seibyl; Tristan D McClure-Begley; Marina R Picciotto; Irina Esterlis
Journal:  Biol Psychiatry       Date:  2013-06-14       Impact factor: 13.382

10.  Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder.

Authors:  Joanna Szczepanik; Allison C Nugent; Wayne C Drevets; Ashish Khanna; Carlos A Zarate; Maura L Furey
Journal:  Psychiatry Res Neuroimaging       Date:  2016-06-20       Impact factor: 2.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.